> Details

Nassif, Elise F.; Cope, Brandon; Traweek, Raymond; Witt, Russell G.; Erstad, Derek J.; Scally, Christopher P.; Thirasastr, Prapassorn; Zarzour, Maria Alejandra; Ludwig, Joseph; Benjamin, Robert; Bishop, Andrew J.; Guadagnolo, B. Ashleigh; Ingram, Davis; Wani, Khalida; Wang, Wei‐Lien; Lazar, Alexander J.; Torres, Keila E.; Hunt, Kelly K.; Feig, Barry W.; Roland, Christina L.; Somaiah, Neeta; Keung, Emily Z.

Real‐world use of palbociclib monotherapy in retroperitoneal liposarcomas at a large volume sarcoma center

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Real‐world use of palbociclib monotherapy in retroperitoneal liposarcomas at a large volume sarcoma center
  • Contributor: Nassif, Elise F.; Cope, Brandon; Traweek, Raymond; Witt, Russell G.; Erstad, Derek J.; Scally, Christopher P.; Thirasastr, Prapassorn; Zarzour, Maria Alejandra; Ludwig, Joseph; Benjamin, Robert; Bishop, Andrew J.; Guadagnolo, B. Ashleigh; Ingram, Davis; Wani, Khalida; Wang, Wei‐Lien; Lazar, Alexander J.; Torres, Keila E.; Hunt, Kelly K.; Feig, Barry W.; Roland, Christina L.; Somaiah, Neeta; Keung, Emily Z.
  • imprint: Wiley, 2022
  • Published in: International Journal of Cancer
  • Language: English
  • DOI: 10.1002/ijc.33956
  • ISSN: 0020-7136; 1097-0215
  • Keywords: Cancer Research ; Oncology
  • Origination:
  • Footnote:
  • Description: <jats:title>Abstract</jats:title><jats:p>Palbociclib has been evaluated in early phase trials for well‐differentiated liposarcoma (WDLPS) and dedifferentiated liposarcoma (DDLPS) patients, with reported median progression‐free survival (PFS) of 18 weeks. Here, we report on real‐world use and surgical outcomes associated with palbociclib treatment. We retrospectively reviewed 61 consecutive patients with retroperitoneal WDLPS (n = 14) or DDLPS (n = 47) treated with palbociclib monotherapy between 1 March 2016 and 28 February 2021 at The University of Texas MD Anderson Cancer Center. At palbociclib initiation, median age was 64 (interquartile range [IQR] 56‐72). In WDLPS and DDLPS cohorts, the median number of prior systemic treatments was 0 (IQR 0‐0) and 2 (IQR 0‐4), respectively. Median number of prior surgeries was 2 (WDLPS IQR 1‐2.75) and 2 (DDLPS IQR 1‐3). Median PFS was 9.2 (WDLPS IQR 3.9‐21.9) and 2.6 months (DDLPS IQR 2.0‐6.1), with median time on treatment of 7.4 months (WDLPS IQR 3.5‐14.2) and 2.7 months (DDLPS IQR 2.0‐5.7). Twelve patients ultimately underwent surgical resection. Resections were macroscopically complete (R0/R1) in half (n = 6/12), among whom only one patient experienced relapse after resection (median follow‐up 7.5 months). All patients who underwent macroscopically incomplete resections progressed after surgery with median time to progression of 3.3 months (IQR 2.3‐4.4). Surgery after palbociclib treatment was not associated with improved overall survival. Efficacy of palbociclib monotherapy for patients with advanced WDLPS and DDLPS is disappointing. While palbociclib may have been used to delay surgery, there was no clear benefit from treatment and few patients achieved prolonged tumor control.</jats:p>
  • Access State: Open Access